Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00261625|
Recruitment Status : Completed
First Posted : December 5, 2005
Last Update Posted : January 5, 2009
|Condition or disease||Intervention/treatment||Phase|
|End-Stage Renal Disease Osteoporosis||Drug: alendronate||Phase 4|
The study is a prospective, randomized cross-over study. Fifty patients will be included. All participants are randomly allocated to either group 1 or group 2. Each group consists of 25 patients. Group 1 patients receive alendronate 70 mg once weekly in the first 24 weeks of the study, while group 2 patients receive the same dose of drug every week in the second 24 weeks. The extent of coronary artery and aortic calcification is evaluated by using multidetector spiral computed tomography, whereas bone mineral density is measured by dual-energy X-ray absorptiometry. Both examinations are performed at week 0, 24 and 48 for each participant. Serum level of calcium should be kept within normal limits and serum level of phosphorus should be kept below 6 mg/dl.
Administration of Alendronate
One tablet of alendronate (70 mg per tablet) should be swallowed by each patient once every week with water at least 30 minutes before breakfast, beverage or medication of the day during the treatment period. Patients must not lie down for at least 30 minutes after taking the drug.
Measurement of Coronary Artery and Aortic Calcification
Multidetector spiral computerized tomography (CT) of the chest is performed at week 0, 24 and 48 for each participant to measure the extent of coronary and aortic calcification.
Measurement of Bone Density
Dual energy X-ray absorptiometry is performed at week 0, 24 and 48 for each participant to measure the density of bone.
Demographic and Clinical Characteristics of Patients
Patients characteristics such as age and sex are documented. Clinical parameters including body height, body weight, duration of dialysis, calcium concentration of dialysate, and medication under use are recorded. Blood pressure is measured at each clinical visit for 3 times after the patient has sit for at least 15 minutes.
Collection of Laboratory Data
Fasting serum levels of albumin, phosphorus, calcium, alkaline phosphatase (ALP), intact parathyroid hormone (iPTH) and hemoglobin level of each patient are checked at study entry and once every month. Fasting serum levels of triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL-chol), low-density lipoprotein cholesterol (LDL-chol), and hypersensitive C-reactive protein (CRP) of each patient are checked at study entry and once every 3 months.
Record of Adverse Effects of Alendronate
Any adverse effect of alendronate is recorded every month at clinic visit.
Compliance of Patients
Compliance of the patients is monitored using telephone calls once every week during the treatment period with alendronate.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients?|
|Study Start Date :||August 2005|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||October 2007|
- extent of aortic and coronary artery calcification with and without the use of alendronate
- bone mineral density with and without the use of alendronate
- serum levels of calcium, phosphorus and parathyroid hormone
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00261625
|Principal Investigator:||Tze-Wah Kao, Master||National Taiwan University|